Francesco Speziale, Laura Capoccia
|
|
|
- Derick Day
- 5 years ago
- Views:
Transcription
1 Results of a multicenter italian registry of real world CAS with the C-Guard mesh covered stent: the IRONGUARD 2 Study Francesco Speziale, Laura Capoccia Vascular Surgery Division Head of Division Prof. Francesco Speziale Department of Surgery Paride Stefanini, Policlinico Umberto I Sapienza University of Rome, ITALY
2 Conflict of Interest I have nothing to disclose
3 200 enrolled patients Technical Success: 100% MACCE=0 5 minor strokes 2 TIAs EuroIntervention 2018
4 @ 1 Year IRONGUARD No major neurological adverse event No stent thrombosis No ECA occlusion EuroIntervention In press
5 Enrollment So we decided to continue our experience with a NEW registry: Up to August 2018, 342 Patients in 15 enrolling Centers 2
6 Demographics Age: 72.5±7.86 yy (48-97) Male Gender: 245 (71.22%) Tobacco Abuse: 112 (32,55%) Diabetes: 125 (36.33%) Hypertension: 291 (84,59%) Dyslipidemia: 251 (72.96%) CAD: 107 (31.10%)
7 50 out of 342 patients (14.53%) were symptomatic 36 TIAs (72%) Symptoms 14 Minor Strokes (28%) Minor Stoke TIA
8 Target Lesions Stenosis 84.97±6.51% (50-99) Stenosis
9 Plaques Composition Hyperechoic 102 (29.65%) Hypoechoic 77 (22.38%) Isoechoic 45 (13.08%) Disomogeneous 80 (23.25%) Ulcerated 12 (4.09%) Thin fibrous Cap 5 (1.45%) Post-CEA restenosis 21 (6.10%) 97 (28.79%) presented an high-risk carotid plaque
10 Arch Anatomies Type I 135 (39.47%) Type II 161 (47.07%) Type III 12 (3.51%) Bovine 34 (6.10%) All aortic arch morphologies were enrolled in the study
11 Arch Anatomies Thrombosis 15 (4.38%) Calcifications 89 (26.02%) Moderate/Severe Tortuosity 120 (35%) 1/3 of enrolled patients presented significant supraaortic vessels tortuosity
12 Procedural Details Almost in all cases a transfemoral approach was chosen (98.24%), while also brachial (0.88%) and transcervical approaches (0.88%) were reported
13 Procedural Details Embolic Protection Device was adopted in 99.70% of patients. Proximal occlusion device (Mo.Ma.) in 50 (14.62%), and distal filter in 291 (85.08%)
14 Procedural Details Pre-dilatation 89 (26.02%) Post-dilatation 286 (83.26%) Atropine 216 (63.15%) Contrast amount 61.78±37.72ml
15 Post-Procedural (24h) Results 5 TIAs 1 Minor Strokes No AMI No Death 2 ECA occlusions 4 Severe Bradycardias 1.75%
16 @ 1 Month Results Data available on 255 Pts 2 additional neurological events (1 TIA, 1 Minor Stroke) No AMI No Death NO STENT THROMBOSIS ACE patency 97.60%
17 @ 1 Month cumulative Results Minor Stroke rate 0.58% (n=2) TIA rate 1.72% (n=6) Cumulative neurological event rate 2.33%
18 @ 1 Year Results Data available on 57 Pts 1 new MACE: IMA (fatal), no new neurological event 2 Deaths: AMI Suicide ACE patency 96.49%
19 Conclusions Ongoing analysis!!! We are still recruiting patients
20 P.I. Francesco Speziale Laura Capoccia Michelangelo Ferri Bruno Gossetti Franco Intrieri Arnaldo Ippoliti Wassim Mansour Paolo Mortola Thanks to all Domenico Palombo Sonia Ronchey Massimo Ruggeri Maria Antonella Ruffino Pasqualino Sirignano Francesco Spinelli Massimo Sponza Maurizio Taurino
21 Symposium Chairman Francesco Speziale Scientific Secretariat Laura Capoccia Wassim Mansour Pasqualino Sirignano Vascular and Endovascular Surgery Division Department of Surgery Paride Stefanini Sapienza University of Rome Policlinico Umberto I caput.meeting@gmail.com
Innovation forum EVAR
Innovation forum EVAR Preliminary results of expanding indications for treatment with standard EVAR in patients with challenging anatomies, a multi-centric prospective evaluation (EXTREME) study Pasqualino
Sealing con polimero e stent sovra renali nei colleti difficili
Forum tecnico su Sealing, fissazione e Endoleaks in EVAR Sealing con polimero e stent sovra renali nei colleti difficili Francesco Speziale Chief Vascular and Endovascular Surgery Division Department of
UTILIZZO DI AFX (ENDOLOGIX) STENTGRAFT IN PAZIENTI CON PATOLOGIA AORTO-ILIACA TASC-D E ANEURISMA DELL AORTA ADDOMINALE
IN PAZIENTI CON PATOLOGIA AORTO-ILIACA TASC-D E ANEURISMA DELL AORTA ADDOMINALE C.F. Porreca, P. Sirignano, W. Mansour, M. Formiconi, M. Brunoro, L. Capoccia, F. Speziale Vascular and Endovascular Surgery
CAS as first line of treatment in the future
Azienda Ospedaliera Universitaria Senese CHIRURGIA VASCOLARE Chief:Prof. Carlo Setacci CAS as first line of treatment in the future Prof. Carlo Setacci Chief of Vascular Surgery University of Siena - Italy
Carlo Setacci Chief Department of Surgery Vascular and Endovascular Unit University of Siena
Which carotid procedures are required to grade the stroke risk? Carlo Setacci Chief Department of Surgery Vascular and Endovascular Unit University of Siena Faculty disclosure Carlo Setacci I have no financial
Tips and Tricks for CAS T-CAR
Tips and Tricks for CAS T-CAR H.-H. Eckstein, M. Kallmayer Department for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University of Munich,, Germany Disclosures Collaborator
Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL
Carotid Technologies and Protection Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL Disclosure Statement
Impact of the Aortic Arch on Stent Performance
Impact of the Aortic Arch on Stent Performance GianLuca Faggioli Vascular Surgery Alma Mater Studiorum UniversitY of Bologna ACST-2 Indications for carotid stenting: a preview of the potential derived
New ischemic brain lesions on DW-MRI after CAS with double layer stent
New ischemic brain lesions on DW-MRI after CAS with double layer stent Maria Antonella Ruffino, MD, EBIR, Claudio Rabbia, MD Vascular Radiology Città della Salute e della Scienza San Giovanni Battista
Carotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA
Carotid Artery Stenting (CAS) Carotid Artery Stenting for Stroke Risk Reduction Matthew A. Corriere MD, MS, RPVI Assistant Professor of Surgery Department of Vascular and Endovascular Surgery Rationale:
Carotid Artery Stent: Is it ready for prime time?
2010 CATH LAB SYMPOSIUM Carotid Artery Stent: Is it ready for prime time? Luis F. Tami, MD, FACC, FSCAI Interventional Cardiology and Vascular Medicine Memorial Regional Hospital August 2010 CAE and CAS
Review of clinical carotid stent procedural & long-term outcomes in. symptomatic asymptomatic. patients
Review of clinical carotid stent procedural & long-term outcomes in symptomatic asymptomatic patients 1 Conflict of Interest Statement Within the past 12 months, I or my spouse have had a financial interest/arrangement
Subclavian artery Stenting
Subclavian artery Stenting Etiology Atherosclerosis Takayasu s arteritis Fibromuscular dysplasia Giant Cell Arteritis Radiation-induced Vascular Injury Thoracic Outlet Syndrome Neurofibromatosis Incidence
Carotid Artery Stenting
Carotid Artery Stenting Natural history of the carotid stenosis Asymptomatic 80% carotid stenosis - 6% risk of stroke / year Symptomatic carotid stenosis have 10% risk of CVA at one year and 40% at 5 years
New concepts for filter protection during CAS: double filtration. Alberto Cremonesi MD, FESC
New concepts for filter protection during CAS: double filtration Alberto Cremonesi MD, FESC First Experience with the PALADIN Carotid Post-Dilation Balloon with Integrated Embolic Protection Alberto Cremonesi
Filters versus Occlusion Balloons during CAS Is there a clear preference?
Washington TCT 2005 Filters versus Occlusion Balloons during CAS Is there a clear preference? K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany Presenter Disclosure Information
Surgical Treatment of Carotid Disease
Department of Cardiothoracic & Vascular Surgery McGovern Medical School / The University of Texas Health Science Center at Houston Surgical Treatment of Carotid Disease The Old, the New, and the Future
Limitations of Other Embolic Protection Devices - Filters. Carotid Stenting with Flow Reversal. Limitations of Distal Occlusion
Carotid Stenting with Flow Reversal Marc Schermerhorn, MD Division of Vascular and Endovascular Surgery Beth Israel Deaconess Center Boston, MA Limitations of Other Embolic Protection Devices - Filters
FRANK J. VEITH MAC TH MUNICH VASCULAR CONF
UPDATE ON THE NORTH AMERICAN RCTs CREST 2 & ACST 1: WILL CAS SURVIVE AS AN ALTERNATIVE TO BMT OR CEA? FRANK J. VEITH 6 TH MUNICH VASCULAR CONF MAC - 2016 MUNICH DECEMBER 1, 2016 I HAVE NO FINANCIAL CONFLICTS
Avoiding and Managing Complications During CAS: Lessons Learned
LINC 2019 Leipzig, Germany, Jan 22-25, 2019 Avoiding and Managing Complications During CAS: Lessons Learned Horst Sievert, Ilona Hofmann, Kolja Sievert, Laura Vaskelyte, Sameer Gafoor, Stefan Bertog, Predrag
Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC
Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC GVM Care & Research - Cardiovascular Department (Cotignola Italy) Hypothesis: Does CAS present similar outcomes than
The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent
The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent 6 month data Piotr Musialek, MD DPhil FESC Jagiellonian University Dept. of Cardiac & Vascular Diseases John
proximal protection with the MO.ma device during carotid stenting
proximal protection with the MO.ma device during carotid stenting Robert M. Bersin, MD, MPH, FACC, FSCAI Medical Director, Endovascular Services Seattle Cardiology and Swedish Medical Center -1- proximal
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
M AY. 6. 2011 10:37 A M F D A - C D R H - O D E - P M O N O. 4147 P. 1 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control
MINERVA MEDICA COPYRIGHT
SPECIAL ARTICLES J CARDIOVASC SURG 2015;56:787-91 Physician-initiated prospective Italian Registry of carotid stenting with the C-Guard mesh-stent: the IRON-Guard registry. Rationale and design According
PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!!
PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!! Prof Piotr Pieniazek MD PhD Jagiellonian University Institute of Cardiology, John Paul II Hospital Krakow, Poland
New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
Roadsaver the paradigm shift in carotid artery treatment. G. Torsello Münster
Roadsaver the paradigm shift in carotid artery treatment G. Torsello Münster Disclosure Speaker name:...g. Torsello... I have the following potential conflicts of interest to report: Consulting Employment
Carotid Stenting and Surgery in 2016 in Russia
Carotid Stenting and Surgery in 2016 in Russia Novosibirsk research institute of circulation pathology named by Meshalkin, Novosibirsk, Russia Starodubtsev V., Karpenko A., Ignatenko P. Annually in Russia
Carotid Artery Stenting
Carotid Artery Stenting Woong Chol Kang M.D. Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Carotid Stenosis and Stroke ~25% of stroke is due to carotid disease, the reminder
Evaluation of a new micromesh carotid stent with Optical Coherence Tomography.
Evaluation of a new micromesh carotid stent with Optical Coherence Tomography. Technical case report. J. Lemoine,S. Myla,Z. Chati,R.Aslam, M.Amor Clinic Louis Pasteur,Essey les Nancy.France Disclosure
CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai
CardioLucca2014 Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee Fabrizio Tomai European Hospital e Aurelia Hospital Roma Treatment of Carotid Artery Disease
Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion
Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion Paul Hsien-Li Kao, MD Assistant Professor National Taiwan University Medical School and Hospital ICA stenting
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA What are the possible causes of stroke in CAS? Operator error Technique (balloon sizing, wire misadventure, EPD
Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
BULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial
BULgarian Carotid Artery Stenting versus Surgery Study (): Randomized single center trial Ivo Petrov, M. Konteva, H. Dimitrov, K. Kichukov Tokuda Hospital Sofia Cardiology Department Background Carotid
Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACAS (Asymptomatic Carotid Atherosclerosis Study), 65 66 ACST (Asymptomatic Carotid Surgery Trial), 6 7, 65, 75 Age factors, in carotid
CAROTID ARTERY STENTING TECHNICALS ASPECTS. Symposium Abbott Vascular CANNES MEET 2008 Drs V PIRET, P BERGERON
CAROTID ARTERY STENTING TECHNICALS ASPECTS Symposium Abbott Vascular CANNES MEET 2008 Drs V PIRET, P BERGERON POINTS TO DISCUSS TO CAS INDICATIONS CONTRA INDICATIONS ANATOMICAL CONSIDERATION TECHNICS CAS
Hidden coronary disease in carotid patients
6 th ACST-2 Collaborators Meeting in Valencia, Spain 24th and 25th September 2018 Hidden coronary disease in carotid patients Valerio Tolva Policlinico di Monza Italy Are we always aware of coronary anatomy?
DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC LEIPZIG JANUARY 27, 2015
DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC - 2015 LEIPZIG JANUARY 27, 2015 Disclosure Speaker name: FRANK J. VEITH DESPITE SOME
Carotid Artery Stenting
Carotid Artery Stenting JESSICA MITCHELL, ACNP CENTRAL ILLINOIS RADIOLOGICAL ASSOCIATES External Carotid Artery (ECA) can easily be identified from Internal Carotid Artery (ICA) by noticing the branches.
Future Perspectives of Micromesh Stents Antonio Micari MD Director Cardiovascular Units GVM Care and Research (Palermo, Italy)
Future Perspectives of Micromesh Stents Antonio Micari MD Director Cardiovascular Units GVM Care and Research (Palermo, Italy) Potential conflicts of interest Antonio Micari MD I have the following potential
Comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study
Comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study (RADial access for CARotide artery stenting) Zoltán Ruzsa MD PhD et al. TCT 2013 Disclosure Statement of Financial
Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014
Carotid Artery Revascularization: Current Strategies Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Disclosures None 1 Stroke in 2014 Stroke kills almost
SCAI Fall Fellows Course Subclavian/Innominate Case Presentation
SCAI Fall Fellows Course 2012 Subclavian/Innominate Case Presentation Daniel J. McCormick DO, FACC, FSCAI Director, Cardiovascular Interventional Therapy Pennsylvania Hospital University of Pennsylvania
Carotid Revascularization
Options for Carotid Disease Carotid Revascularization Wayne Causey, MD 2 nd Year Vascular Surgery Fellow Best medical therapy, Carotid Endarterectomy, and Carotid Stenting Who benefits from best medical
Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease
Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Michael R. Jaff, D.O., F.A.C.P., F.A.C.C. Assistant Professor of Medicine Harvard Medical School Director, Vascular Medicine
TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS
TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS Assistant Professor of Surgery Director of Carotid Interventions Division of Vascular & Endovascular Surgery Stony Brook University
Micromesh technology in carotid artery treatment what is next? Max Amor MD Clinique Louis Pasteur, Essey-Les-Nancy France
Micromesh technology in carotid artery treatment what is next? Max Amor MD Clinique Louis Pasteur, Essey-Les-Nancy France www.incathlab.com Disclosure Speaker name: Max Amor, MD.... I have the following
Why I m afraid of occlusive devices
Why I m afraid of occlusive devices Cannes 28.06.2008 Carlo Cernetti Cardiology Department Mirano (Venice) MEET 2008 CANNES I HAVE NOT FINACIAL INTEREST/ARRANGEMENT OR AFFILIATION CONFLICT Obstructive
Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective)
Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective) T-Woei Tan, MD, FACS, RPVI Assistant Professor of Surgery Vascular and Endovascular Surgery Louisiana State University Health -
Carotid Disease and CABG: What is the best Treatment
Carotid Disease and CABG: What is the best Treatment Dual Antiplatelets Luis A Guzman, MD, FACC, FSCAI Professor of Medicine Director, Cardiovascular Cath Lab Virginia Commonwealth University Stroke during
Carotid Revascularization 20 Years From Now
Carotid Revascularization 20 Years From Now Kenneth Rosenfield, MD, MHCDS, MSCAI Section of Vascular Medicine and Intervention Cardiology Division MGH, Boston, MA In 2036, if we are all still alive This
Update from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
TCD in Subclavian Steal Syndrome
ISSN 2005-7881 Journal of Neurosonology 2(Suppl. 1):25-30, 2010 TCD in Subclavian Steal Syndrome Soon-Tae Lee, M.D., Ph.D. Department of Neurology, Seoul National University Hospital, Seoul, South Korea
a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers
The study a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers Conflict of interest have the following potential conflicts of interest to report: Consulting
Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii
Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have the following potential conflicts of
Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI
Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI Director, Peripheral Vascular Interventional Laboratory Director, Vascular & Endovascular Medicine Fellowship Program Assistant Professor of Medicine The
TCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
Prevention and Management of Cardiac Adverse Event
Prevention and Management of Cardiac Adverse Event Carlo Cernetti Department of Interventional Cardiology Mirano (Italy) Cannes MEEC 14 June 2007 Are these risks factors of Haemodynamic Instability
Alma Mater Studiorum Università di Bologna
Alma Mater Studiorum Università di Bologna S.Orsola-Malpighi, Bologna, Italia Chirurgia Vascolare The volume of cerebral ischaemic lesion predicts the outcome after symptomatic carotid revascularisation
high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy
Alternate Vascular Access for TAVR Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no relevant financial relationships Transcatheter Valves
Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery
Treatment Considerations for Carotid Artery Stenosis Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery 4.29.2016 There is no actual or potential conflict of interest in regards to this presentation
VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD
VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Aims of Valve Academic Research Consortium (VARC) (i) selecting appropriate
CAROTID ARTERY ANGIOPLASTY
CAROTID ARTERY ANGIOPLASTY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
Subclavian Revascularization. Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014
Subclavian Revascularization Douglas E. Drachman, MD, FSCAI Division of Cardiology Vascular Medicine Section December 9, 2014 Disclosure Information Douglas E. Drachman, MD, FACC Abbott Vascular, Inc.:
PREDICTORS OF PERI-PROCEDURAL OUTCOMES OF CAS A REAL WORLD EXPERIENCE
PREDICTORS OF PERI-PROCEDURAL OUTCOMES OF CAS A REAL WORLD EXPERIENCE B. PATRICE MWIPATAYI, MMed, FCS (SA), FRACS, GD-CLINED (Melb) Department of Vascular Surgery, RPH School of Surgery, University of
Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
The SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
Clinical Study Contralateral Occlusion Increases the Risk of Neurological Complications Associated with Carotid Endarterectomy
International Vascular Medicine Volume 2015, Article ID 942146, 8 pages http://dx.doi.org/10.1155/2015/942146 Clinical Study Contralateral Occlusion Increases the Risk of Neurological Complications Associated
Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO
Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Goal of treatment of carotid disease Identify those at risk of developing symptoms Prevent patients at risk from developing symptoms Prevent
Santi Trimarchi, MD, PhD Vascular Surgeon Thoracic Aortic Research Center, Director IRCCS Policlinico San Donato University of Milan
The Gore GREAT Registry: Update about a real life data collection Santi Trimarchi, MD, PhD Vascular Surgeon Thoracic Aortic Research Center, Director IRCCS Policlinico San Donato University of Milan Disclosures
Case Closed Closed cell stent technology
Sponsored by Boston Scientific Corporation Case Closed Closed cell stent technology for carotid artery disease. Innovations in device technologies have helped to raise the bar for clinical efficacy in
Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy.
Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy. GENNARO SARDELLA, MD, FACC,FESC; MASSIMO MANCONE,
Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine
Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Institute The Oregon Clinic Disclosure I declare that neither
UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?
UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE? Richard W. Petrella M.D. FACP,FACC,FASCI DEPARTMENT CHAIRMAN CVM&S UPMC HAMOT MEDICAL CENTER 1 LEARNING OBJECTIVES REVIEW THE RISK FACTORS FOR
Nitinol micromesh technology for Carotid artery treatment. Max Amor Julien Lemoine Clinique Louis Pasteur, Essey-lès-Nancy
Nitinol micromesh technology for Carotid artery treatment Max Amor Julien Lemoine Clinique Louis Pasteur, Essey-lès-Nancy max.amor@incathlab.com NICE JUNE 2016 Disclosure Speaker name: Max Amor, MD....
Efficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
Embolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
Update on Carotid Stenting. John R. Laird Cardiovascular Research Institute Washington Hospital Center
Update on Carotid Stenting John R. Laird Cardiovascular Research Institute Washington Hospital Center Carotid Stenting What a Crazy Idea! Pathogenesis of stroke Does it make sense to think that expansion
Contemporary management of brachiocephalic occlusive disease. TM Sullivan Minneapolis, MN
Contemporary management of brachiocephalic occlusive disease TM Sullivan Minneapolis, MN WL Gore & Associates Disclosures Meeting organizer (SOAR) CR Bard Chair, CEC Bolster trial Veryan National PI, MIMICS
Algorithmic selection of emboli protection device during the procedure of carotid artery stunting
Algorithmic selection of emboli protection device during the procedure of carotid artery stunting Yasuhiro Kawabata, Tetsuya Tsukahara, Shunichi Fukuda, Tomokazu Aoki, Satoru Kawarazaki Department of Neurosurgery,
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #344: Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Effective Clinical
ROADSTER 2. SPONSOR: Silk Road Medical
ROADSTER 2 CONDITION: Carotid artery disease PI: Jessica Titus, MD CONTACT INFO: Jo Anne Goldman JoAnne.Goldman@allina.com 612-863-3793 DESCRIPTION: The study is intended to evaluate real world usage of
Subclavian Artery Plug Embolization (SAPE study): a real experience about endovascular subclavian occlusion prior to thoracic vascular repair
Subclavian Artery Plug Embolization (SAPE study): a real experience about endovascular subclavian occlusion prior to thoracic vascular repair Simone Salvati, Luca Bertoglio, Alessandra Fittipaldi, Andrea
SCAFFOLD Study Gore PTFE mesh-covered stent preclinical and clinical data so far. Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii
SCAFFOLD Study Gore PTFE mesh-covered stent preclinical and clinical data so far Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have the following
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
SAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D
SAMMPRIS Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis Khalil Zahra, M.D Major points Patients with recent TIA or stroke and intra-cranial artery
Early Clinical Results with the Valiant Mona LSA Branch Stent-Graft
Early Clinical Results with the Valiant Mona LSA Branch Stent-Graft Frank R. Arko III, MD Professor of Cardiovascular Surgery Director, Endovascular Surgery Co-Director, Aortic Institute Carolinas Medical
Welcome to the 8 th European Bifurcation Club October Barcelona
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Safety and clinical efficacy of Sideguard stent for treatment of bifurcation lesions Interim results from European multicentre
CAROTID ANGIOPLASTY AND STENTING UNDER PROTECTION IS BECOMING THE GOLD STANDARD TREATMENT IN HIGH AND LOW RISK PATIENTS
CAROTID ANGIOPLASTY AND STENTING UNDER PROTECTION IS BECOMING THE GOLD STANDARD TREATMENT IN HIGH AND LOW RISK PATIENTS M. HENRY* MD, I. HENRY MD A. POLYDOROU MD, A.D. POLYDOROU MD M. HUGEL RN NANCY FRANCE
ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH
ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME: INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH AUTHORS: Marta Ponte 1, RICARDO
Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
Percutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
Accessi Iliaci Ostili
Alma Mater Studiorum Bologna University S.Orsola-Malpighi, Bologna, Italy Vascular Surgery Accessi Iliaci Ostili nel trattamento della patologia aortica E. Gallitto Iliac Navigations Alma Mater Studiorum